| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RAPID REPORT |
1
Department of Physiology, University of Birmingham, Birmingham B15 2TT, UK
2
Henry Wellcome Building of Molecular Physiology, Oxford, OX3 9 DU, UK
Hypoxia-inducible factor (HIF) modulates transcriptional control of several genes involved in vascular growth and cellular metabolism. HIF activity can be enhanced by suppression of prolyl and asparaginyl hydroxylase activity by dimethyloxalylglycine (DMOG). We have compared the effects of DMOG treatment and femoral artery ligation individually or in combination on HIF-1
protein level, HIF-dependent gene expression and capillary-to-fibre ratio (C: F) in extensor digitorum longus and tibialis anterior muscles of mice. Immunohistochemical examination revealed that HIF-1 is present in non-ischaemic mouse skeletal muscles, but its amount increased profoundly in response to the combination of DMOG treatment and ischaemia. Combined treatment resulted in 39% increase in C: F in ischaemic muscles (P < 0.0001 versus controls) whereas individual treatments produced little effect under our conditions. Combined treatment led to a significant increase in endogenous HIF-1 protein (6.14 ± 1.1 versus 1.17 ± 0.2 in controls; P < 0.05) that was not apparent in mice treated with DMOG or femoral artery ligation alone. Ischaemia increased vascular endothelial growth factor (VEGF) protein production by 2.5-fold (P < 0.05 versus controls), irrespective of DMOG treatment. However, production of the VEGF receptor Flk-1 was more enhanced in ischaemic + DMOG-treated muscles (P < 0.001 and P < 0.05 compared with controls and untreated ischaemic muscles, respectively), which may explain the intensive growth of capillaries in those muscles. The findings indicate that treatment with DMOG has a potential therapeutic use in promoting angiogenesis in ischaemic diseases, and perhaps for improving muscle recovery after injury, exercise or training.
(Received 8 June 2004;
accepted after revision 13 August 2004;
first published online 19 August 2004)
Corresponding author S. Egginton: Department of Physiology, University of Birmingham, Birmingham B15 2TT, UK. Email: s.egginton{at}bham.ac.uk
This article has been cited by other articles:
|
|
 |
|
  P. Hill, D. Shukla, M. G.B. Tran, J. Aragones, H. T. Cook, P. Carmeliet, and P. H. Maxwell Inhibition of Hypoxia Inducible Factor Hydroxylases Protects Against Renal Ischemia-Reperfusion Injury J. Am. Soc. Nephrol., January 1, 2008; 19(1): 39 - 46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Ji, F. Mac Gabhann, and A. S. Popel Skeletal muscle VEGF gradients in peripheral arterial disease: simulations of rest and exercise Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3740 - H3749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dehne, U. Kerkweg, T. Otto, and J. Fandrey The HIF-1 response to simulated ischemia in mouse skeletal muscle cells neither enhances glycolysis nor prevents myotube cell death Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2007; 293(4): R1693 - R1701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Milkiewicz, J. L. Doyle, T. Fudalewski, E. Ispanovic, M. Aghasi, and T. L. Haas HIF-1{alpha} and HIF-2{alpha} play a central role in stretch-induced but not shear-stress-induced angiogenesis in rat skeletal muscle J. Physiol., September 1, 2007; 583(2): 753 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Adair Growth regulation of the vascular system: an emerging role for adenosine Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2005; 289(2): R283 - R296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Pisani and C. A. Dechesne Skeletal Muscle HIF-1{alpha} Expression Is Dependent on Muscle Fiber Type J. Gen. Physiol., July 25, 2005; 126(2): 173 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Markkanen, T. T. Rissanen, A. Kivela, and S. Yla-Herttuala Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart-gene therapy Cardiovasc Res, February 15, 2005; 65(3): 656 - 664. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
